RAPID Compresses Medicare Coverage to Months

CMS and the FDA jointly announced the Regulatory Alignment for Predictable and Immediate Device pathway on April 23, a Medicare coverage program that allows a proposed national coverage determination to be issued the same day a breakthrough device receives FDA marketing authorization. According to MedTech Dive, current Medicare coverage decisions take roughly a year. Under RAPID, that timeline can compress to as little as two months. At HRS 2026 the same week, Boston Scientific reported pivotal first-line persistent AFib data for Farapulse, and Medtronic’s Sphere-9 catheter for ventricular tachycardia received FDA breakthrough designation. SquareMind closed $18 million for an AI-powered skin-imaging robot, with Sonder Capital, the firm co-founded by Intuitive Surgical’s Fred Moll, leading the round. Read together, the week reset the timing math for any breakthrough-eligible device company in the U.S. market.

CMS and FDA Launched RAPID for Same-Day Medicare Coverage Decisions

The Centers for Medicare and Medicaid Services and the Food and Drug Administration unveiled the Regulatory Alignment for Predictable and Immediate Device pathway on April 23, according to MedTech Dive. Under RAPID, evidence generated for FDA review can support Medicare coverage decisions, and CMS can issue a proposed national coverage determination on the same day the device receives FDA marketing authorization. Eligibility requires the device to be FDA-designated breakthrough, addressing an unmet clinical need for Medicare beneficiaries, and either a Class III device or a Class II device participating in FDA’s Total Product Life Cycle Advisory Program. CMS estimates roughly 40 devices currently qualify with another 20 potentially eligible. The Transitional Coverage for Emerging Technologies pathway will pause for new candidates as CMS focuses on RAPID implementation.

The strategic implication for founders building breakthrough-eligible devices is meaningful and underappreciated. Under the prior model, the gap between FDA clearance and Medicare coverage was a known capital trap. A device cleared without coverage in hand had to fund a year of commercial activity, evidence generation, and reimbursement work against revenue that hospitals could not yet recover from CMS at scale. The capital plan, the hiring plan, and the salesforce plan all assumed that gap. RAPID does not eliminate the work, but it changes the time horizon over which the work has to be funded. A founder running a breakthrough-eligible device program now has a credible path to commercial revenue inside 90 days of FDA marketing authorization rather than 12 to 18 months. The financing implications are significant for any device that fits the eligibility criteria.

Boston Scientific’s AVANT GUARD Trial Cleared a First-Line PFA Position in Persistent AFib

Boston Scientific reported AVANT GUARD trial results at HRS 2026 showing pulsed field ablation outperformed antiarrhythmic drug therapy as a first-line treatment for persistent atrial fibrillation, per MedTech Dive. The 440-patient study compared the Farawave catheter to drug therapy and reported 12-month effectiveness of 56% for PFA versus 30% for drugs, with a major adverse event rate of 5.1%. The data was published in the New England Journal of Medicine. Boston Scientific framed the result as supporting an expansion of the Farapulse approval beyond drug-resistant cases, opening a market the company estimates at roughly $1 billion for persistent AFib treatment by 2028.

The structural lesson for founders building in any contested category is what Boston Scientific just demonstrated about evidence sequencing. Farapulse won initial approval in paroxysmal AFib. The persistent AFib indication was a separate clinical population with separate evidence requirements, and the company invested in a randomized trial against the standard-of-care alternative. The AVANT GUARD result is now both a label-expansion driver and a reimbursement-grade evidence asset that travels into procurement conversations with cardiology programs nationally. Founders whose evidence strategy stops at the initial indication leave the most valuable expansion move on the table. The category leaders are running the next-indication trial in parallel with launch, not after launch.

Medtronic’s Sphere-9 in Ventricular Tachycardia Earned FDA Breakthrough Designation

Medtronic presented late-breaking early feasibility data for the Affera mapping and ablation system with the Sphere-9 catheter in post-MI ventricular tachycardia at HRS 2026, with 65.5% of patients remaining VT-free at six months, according to MedTech Dive. Concurrent with the data, the FDA granted Sphere-9 breakthrough device designation for VT treatment, and a U.S. pivotal trial has been authorized. The combination of a breakthrough designation and post-MI VT data positions Sphere-9 directly inside the eligibility window for the new RAPID coverage pathway when the device eventually receives marketing authorization.

For founders building enabling devices in interventional electrophysiology, the read-through is that the breakthrough designation is now an even more strategically valuable regulatory artifact than it was a week ago. The designation has always pulled forward FDA review timelines and signaled clinical importance to investors. Under the new framework, it also unlocks a potential same-day Medicare coverage decision, which substantially compresses the path from clearance to first commercial revenue. If your regulatory strategy is not actively pursuing breakthrough designation for an eligible indication, you are leaving a year of revenue runway on the table.

SquareMind Raised $18 Million for an AI-Powered Skin-Imaging Robot

SquareMind, a Paris-based medical robotics startup, announced an $18 million round to support U.S. and European launches of its AI-powered skin-imaging robot, according to coverage from Tech Startups. The round was led by Sonder Capital, the venture firm co-founded by Intuitive Surgical’s Fred Moll, with participation from Bpifrance’s Deeptech 2030 fund, Adamed Technology, Calm/Storm Ventures, and Teampact Ventures. The product applies robotic imaging to dermatologic screening and is positioned to enter U.S. and European markets in the near term.

Two structural points are worth pulling out for founders thinking about adjacent categories. First, the lead investor signal matters. Sonder Capital is one of a small set of funds whose pattern recognition in surgical and interventional robotics is genuinely deep, and the firm continues to back robotic imaging companies operating in clinical adjacencies to surgery. The investment thesis is that imaging robotics is a category that travels with the surgical robotics ecosystem rather than competing with it. Second, the geographic strategy is a U.S. and European simultaneous launch, not a European-first pattern that would have been more typical for a Paris-based startup five years ago. The capital and regulatory pathways for robotic imaging in the U.S. have moved enough to make a parallel launch feasible at this stage of company maturity. Founders building in robotic imaging or robotic-adjacent diagnostic devices should read that as a market signal about timing.